3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Observational
1
Sponsor
Conditions
Breast Neoplasms
1934
Neoplasms
1387
Carcinoma, Non-Small-Cell Lung
1328
Prostatic Neoplasms
1072
Multiple Myeloma
857
Leukemia, Myeloid, Acute
764
Neoplasm Metastasis
693
Colorectal Neoplasms
679
Melanoma
671
Lung Neoplasms
666
Lymphoma
656
Leukemia
592
Lymphoma, Non-Hodgkin
588
Leukemia, Lymphocytic, Chronic, B-Cell
529
Ovarian Neoplasms
522
Pancreatic Neoplasms
493
Precursor Cell Lymphoblastic Leukemia-Lymphoma
473
Recurrence
466
Myelodysplastic Syndromes
422
Lymphoma, Follicular
407
Head and Neck Neoplasms
402
Carcinoma, Renal Cell
377
Glioblastoma
376
Lymphoma, Large B-Cell, Diffuse
372
Brain Neoplasms
371
Hodgkin Disease
352
Carcinoma, Hepatocellular
325
Squamous Cell Carcinoma of Head and Neck
323
Lymphoma, Mantle-Cell
302
Sarcoma
281
Interventions
VP-102
1
Cantharidin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Has results
×
Skin Diseases, Viral
×
Clear all
NCT03487549
2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
56 enrolled
29 charts
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts